Immune response to second dose of MMR vaccine in Indian children
- PMID: 21985812
- PMCID: PMC3193710
Immune response to second dose of MMR vaccine in Indian children
Abstract
Background & objectives: MMR vaccine in a two dose schedule has successfully eliminated measles, mumps and rubella from many developed countries. In India, it is not a part of national immunization programme but is included in the State immunization programme of Delhi as a single dose between 15-18 months. This prospective study was carried out to assess the extent of seroprotection against these three diseases in immunized children and to study the immune response to a second dose of MMR.
Methods: Consecutive children aged 4-6 yr, attending the immunization clinic of a tertiary care hospital in Delhi for routine DT vaccination, were enrolled. Second dose of MMR was given and pre- and post-vaccination antibody levels were compared.
Results: The pre-vaccination percentage seropositivity observed in the 103 children recruited, was 20.4 per cent for measles, 87.4 per cent for mumps and 75.7 per cent for rubella. Amongst the 84 children who were followed up after the second dose, the percentage seroprotection for measles rose from 21.4 (18/84) to 72.6 per cent (61/84) and 100 per cent became seroprotected to mumps and rubella.
Interpretation & conclusions: The percentage of children protected against measles was found to be alarmingly low which needs to be investigated. Though the observed protection against mumps and rubella was adequate, its durability was not known. The need for re-appraisal of the current MMR immunization policy is called for by carrying out longitudinal studies on a larger sample.
Comment in
-
Time to re-think measles vaccination schedule in India.Indian J Med Res. 2011 Sep;134(3):256-9. Indian J Med Res. 2011. PMID: 21985807 Free PMC article. No abstract available.
Similar articles
-
Comparative evaluation of measles, mumps & rubella vaccine at 9 & 15 months of age.Indian J Med Res. 2003 Nov;118:183-6. Indian J Med Res. 2003. PMID: 14723482 Clinical Trial.
-
Immunogenicity of measles-rubella vaccine administered under India's Universal Immunization Programme in the context of measles-rubella elimination goal: A longitudinal study.Indian J Med Res. 2023 Apr;157(4):250-258. doi: 10.4103/ijmr.IJMR_4113_20. Indian J Med Res. 2023. PMID: 37102515 Free PMC article.
-
Antibodies to measles, mumps, and rubella virus in Thai children after two-dose vaccination at 9 months and 2.5 years: A longitudinal study.Vaccine. 2020 May 19;38(24):4016-4023. doi: 10.1016/j.vaccine.2020.04.013. Epub 2020 Apr 21. Vaccine. 2020. PMID: 32331806 Clinical Trial.
-
Vaccines for measles, mumps, rubella, and varicella in children.Cochrane Database Syst Rev. 2020 Apr 20;4(4):CD004407. doi: 10.1002/14651858.CD004407.pub4. Cochrane Database Syst Rev. 2020. Update in: Cochrane Database Syst Rev. 2021 Nov 22;11:CD004407. doi: 10.1002/14651858.CD004407.pub5. PMID: 32309885 Free PMC article. Updated.
-
Measles, mumps, rubella vaccine (Priorix; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella.Drugs. 2003;63(19):2107-26. doi: 10.2165/00003495-200363190-00012. Drugs. 2003. PMID: 12962524 Review.
Cited by
-
Low Measles Seropositivity in Vaccinated Children.JAMA Netw Open. 2025 Aug 1;8(8):e2529409. doi: 10.1001/jamanetworkopen.2025.29409. JAMA Netw Open. 2025. PMID: 40864465 Free PMC article.
-
Vaccination With Routine Childhood Vaccines and Severity of COVID-19 Among Children in Delhi.Indian Pediatr. 2022 Feb 15;59(2):132-134. doi: 10.1007/s13312-022-2445-1. Epub 2021 Nov 29. Indian Pediatr. 2022. PMID: 34845990 Free PMC article.
-
An infant with congenital rubella syndrome in developing India.BMJ Case Rep. 2017 Nov 28;2017:bcr2017221665. doi: 10.1136/bcr-2017-221665. BMJ Case Rep. 2017. PMID: 29184005 Free PMC article.
-
Measles, the need for a paradigm shift.Eur J Epidemiol. 2019 Oct;34(10):897-915. doi: 10.1007/s10654-019-00569-4. Epub 2019 Oct 17. Eur J Epidemiol. 2019. PMID: 31624970 Review.
-
Immunogenicity and safety of early vaccination with two doses of a combined measles-mumps-rubella-varicella vaccine in healthy Indian children from 9 months of age: a phase III, randomised, non-inferiority trial.BMJ Open. 2015 Sep 11;5(9):e007202. doi: 10.1136/bmjopen-2014-007202. BMJ Open. 2015. PMID: 26362659 Free PMC article. Clinical Trial.
References
-
- Peltola H, Heinonen OP, Valle M, Paunio M, Virtanen M, Karanko V, et al. The elimination of indigenous measles, mumps and rubella from Finland by a 12-year, two dose vaccination program. N Engl J Med. 1994;331:1397–402. - PubMed
-
- Mason WH. Measles. In: Kliegman RM, Behrman RE, Stanton BF, Jenson HB, editors. Nelson textbook of pediatrics. 18th ed. Philadelphia Pa: Saunders Elsevier; 2007. pp. 1331–7.
-
- Mumps virus vaccines. Wkly Epidemiol Rec. 2007;82:49–60. [No authors listed] - PubMed
-
- Singhal T, Amdekar YK, Agarwal RK, editors. IAP guidebook on immunisation, IAP Committee on Immunization 2007-2008. New Delhi: Jaypee Brothers Medical Publishers; 2009. Anonymous. Individual vaccines; pp. 16–98.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources